CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (336)	9/29/1999 11:31:00 PM
From: Vector1	Read Replies (1) of 666

Peter, i am just sick over this. I believe that BEX is a significant advancement in the treatment of low grade NHL,is approvable and will generate substantial sales. At current levels the stock price is ridiculous. I have seen numerous other companies have problems with the FDA. CGPI went through hell getting Periostat approved and the delay cost them a year. The fact of the matter is that the FDA change the rules in the middle of the game all the time. However, I have never seen a company have so much trouble just getting a BLA filing accepted. Apparently the FDA was willing to meet earlier but CLTR demanded senior FDA officials at the meeting and the delay was caused to make sure these senior FDA officials could be there. The company announced this at the Warburg Dillon Reed conference yesterday which explains when the weakness started. Just my opinion by I think that CLTR must believe that some or one of the junior FDA people have not been straight with them and they are making sure that the bigwigs are at the meeting. It may have caused another delay but it may also be a smart strategy. v1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next